St. Elisabeth Krankenhaus GmbH
- Address
- lock Available on a paid plan
Breast Cancer Research
At St. Elisabeth Krankenhaus GmbH in Cologne, the main focus is on neoplasms, especially a broad range of breast cancer studies. The trials explore new treatment options for early, advanced, metastatic, HER2-positive, HER2-negative, and triple-negative disease, with the goal of improving survival, reducing relapse risk, and refining personalized care.
- Testing new targeted therapies and endocrine therapy combinations for hormone receptor-positive breast cancer
- Evaluating treatment effectiveness in HER2-positive, HER2-low, and triple-negative breast cancer
- Studying strategies to prevent recurrence and delay metastatic spread after initial treatment
These studies reflect a strong interest in tailoring breast cancer care to tumor biology and response, with the site contributing actively to both early and advanced disease research.
Ovarian and Female Cancer Studies
The site also conducts trials in female urogenital diseases, with a particular emphasis on ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Research here is aimed at improving first-line treatment, extending progression-free survival, and supporting better outcomes in newly diagnosed advanced disease.
- Assessing new combinations for advanced ovarian cancer
- Comparing maintenance approaches after surgery and chemotherapy
- Exploring ways to improve disease control in high-grade gynecologic cancers
These trials focus on making treatment more effective and durable for women with aggressive cancers of the reproductive system.
Digestive System Cancer Research
Within digestive system diseases, the research portfolio includes studies in colon cancer and rectal cancer. The trials are designed to improve the timing and value of treatment after surgery, especially for patients at higher risk of recurrence.
- Evaluating adjuvant therapy after resection of colon cancer
- Studying preoperative treatment approaches for locally advanced disease
- Using circulating tumor DNA to help guide treatment decisions
This work supports more precise care for colorectal cancer by matching therapy intensity more closely to relapse risk.
Eye Disease Trials
Research in eye diseases at this hospital includes studies for diabetic macular edema and wet age-related macular degeneration. The aim is to improve vision outcomes and evaluate new approaches that may offer more convenient or effective retinal treatment.
- Testing therapies for diabetic macular edema
- Comparing treatment options for wet age-related macular degeneration
- Measuring changes in visual acuity as a key outcome
These ophthalmology studies focus on preserving sight and improving everyday functioning for patients with chronic retinal disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 42 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St. Elisabeth Krankenhaus GmbH
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study Comparing the Efficacy of Vorolanib to Aflibercept in Participants with Diabetic Macular Edema | Eyepoint Inc. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 42 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Letrozole | 5 | Unknown | 2022-04-26 | 2025-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.